(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

162162

(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/046689 A2

(51) International Patent Classification[7]: A61K 31/454, 31/4178, 31/5415, 31/366, 45/06, A61P 3/00, 1/16, 3/06, 3/04, 9/00

(21) International Application Number: PCT/FR2004/002715

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: French

(26) Publication Language: French

(30) Priority Data:

03/12,553	24 October 2003 (24.10.2003)	FR
03/14,763	15 December 2003 (15.12.2003)	FR
04/01,193	5 February 2004 (05.02.2004)	FR
04/03,252	26 March 2004 (26.03.2004)	FR

(71) Applicant *(for all designated States except US)*: SANOFI-AVENTIS [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ARNONE, Michèle [FR/FR]; 39, rue Baudelaire, F-31520 Ramonville Saint-Agne (FR). BENSAID, Mohammed [MA/FR]; 2, allée des Terrasses de Fontcaude, F-34990 Juvignac (FR). HERBERT, Jean-Marc [FR/FR]; 10, rue de l'Amandier, F-31170 Tournefeuille (FR). HESHMATI, Hassan, Massoud [IR/US]; 1815 J.F.K. Boulevard #2514, Philadelphia, PA 19103 (US). JANIAK, Philip [FR/FR]; 3, chemin de la Piocherie, F-91190 Gif-sur-Yvette (FR).

(74) Agent: TSITINI-SOULEAU, Maria; Sanofi-Aventis, 174, avenue de France, F-75013 Paris (FR).

(81) Designated states *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated states *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

As printed

(54) Title: USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITY

(54) Titre : UTILISATION D'UN DERIVE DU PYRAZOLE POUR LA PREPARATION DE MEDICAMENTS UTILES DANS LA PREVENTION ET LE TRAITEMENT DES DYSLIPIDEMIES ET DES MALADIES ASSOCIEES AUX DYSLIPIDEMIES ET/OU A L'OBESITE

(57) Abstract: The invention relates to the use of an antagonistic compound of cannabinoid receptors CB_1, said compound being derived from pyrazole and used alone or associated with another active ingredient, for preparing medicaments for the prevention and treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity, such as the metabolic syndrome, cardiovascular risks and hepatic diseases.

(57) Abrégé : Utilisation d'un composé antagoniste des récepteurs CB_1 aux cannabinoïdes, dérivé du pyrazole, seul ou associé à un autre principe actif, pour la préparation de médicaments utiles dans la prevention et le traitement des dyslipidémies et des maladies associées aux dyslipidémies et/ou à l'obésité telles que le syndrome métabolique, les risques cardiovasculaires et les maladies hépatiques.

WO 2005/046689 A2

G00002